This National Diabetes Awareness Month and World Diabetes Day, Dexcom is asking one simple question: If you could say anything to diabetes, what would you say?Featuring voices from across the global diabetes community,
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2026.
Third Quarter 2026 Financial Highlights:
Revenue grew 11% year-over-year to $1.344 billion on a
The longest-lasting and most accurate1 continuous glucose monitoring (CGM) system authorized by Health Canada will offer people living with diabetes over the age of 18 up to 15.5 days of wear with fewer sensor
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, dating back to the
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the
First-of-its-kind NIL program features 27 athletes with Type 1 diabetes across 13 sports, marking the program’s largest roster to dateDexcom will host "Dexcom U Days" this fall to drive meaningful community and
New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1
New partnership reinforces Dexcom’s commitment to
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer. In
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.
Mr. Boehnlein is a highly accomplished
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.
The live presentation is
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended June 30, 2026.
Second Quarter 2026 Financial Highlights:
Revenue grew 13% year-over-year to $1.308 billion on a
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (NASDAQ:DXCM) on behalf of the company’s long-term investors.
Click here for additional information:
